Medizin
Refine
Year of publication
Document Type
- Article (55)
- Conference Proceeding (1)
- Doctoral Thesis (1)
Language
- English (57) (remove)
Has Fulltext
- yes (57) (remove)
Is part of the Bibliography
- no (57)
Keywords
- brain metastases (2)
- epigenetics (2)
- immunotherapy (2)
- leukemia (2)
- natural killer cells (2)
- Apoptosis (1)
- Autoimmunity (1)
- Bcr-Abl (1)
- CD19 (1)
- CD8+ T-cell mediated tumor suppression (1)
- CIK cells (1)
- CRM1 (1)
- Cancer (1)
- Cancer detection (1)
- Cancer genetics (1)
- Cancer models (1)
- Cardiology (1)
- Cell binding (1)
- Cell differentiation (1)
- Cell plasticity (1)
- Cell signalling (1)
- Cell therapy (1)
- Chromatin and Epigenetics (1)
- Cirrhosis (1)
- Clinical trials (1)
- Erythropoiesis (1)
- Etiology (1)
- Extracorporeal purification (1)
- Gene Regulation (1)
- Gene expression (1)
- Gene therapy (1)
- HIV-1 (1)
- HSPC (1)
- Haematopoietic stem cells (1)
- Hematology (1)
- Hepatocellular carcinoma (1)
- Infectious disease epidemiology (1)
- Jak2(V617F) (1)
- Lactobacillus (1)
- Lectin affinity plasmapheresis (1)
- Liver diseases (1)
- Long non-coding RNAs (1)
- Luciferase (1)
- MALAT1 (1)
- MEIS2 (1)
- Marburg virus (1)
- Membrane staining (1)
- Middle East respiratory syndrome coronavirus (1)
- Multimodal imaging (1)
- NSG mice (1)
- Negative staining (1)
- Oncology (1)
- PBX1 (1)
- Personalized medicine (1)
- Portal hypertension (1)
- Preclinical (1)
- Pseudo HE-images (1)
- RNA interference (RNAi) (1)
- RUNX1/ETO (1)
- Raman spectroscopy (1)
- Self-renewal (1)
- Sequence motif analysis (1)
- Stem cells (1)
- TALE-homdomain protein (1)
- Transcription factors (1)
- Transcriptional control (1)
- Tumor microenvironment (1)
- VHH (1)
- WYE-354 (1)
- activation receptors (1)
- acute lymphoblastic leukemia (1)
- adaptive immune escape (1)
- adoptive cancer immunotherapy (1)
- alpharetroviral vector (1)
- astrocytes (1)
- bone marrow microenvironment (1)
- canonical/non-canonical (1)
- chimeric antigen receptor (1)
- chronic myeloid leukemia (1)
- chronic myeloid leukemia (CML) (1)
- clinical trials (1)
- combination therapies (1)
- congenic mice (1)
- controlled nuclear import (1)
- dendritic cell–tumor cell fusion (1)
- feeder cells (1)
- gallbladder cancer (1)
- gallbladder cancer xenografts (1)
- gene regulation (1)
- gene therapy (1)
- hematopoiesis (1)
- hematopoietic stem and progenitor cells (1)
- history (1)
- human erythroid leukemia (HEL) (1)
- human knockout model (1)
- humanized mouse model (1)
- iPS (1)
- immune surveillance of cancer (1)
- immune system (1)
- innate lymphoid cells (1)
- intracellular trafficking (1)
- knockout mouse (1)
- lentiviral vector (1)
- long non-coding RNA (1)
- mTOR inhibitors (1)
- magnetic resonance imaging (1)
- metabolism (1)
- metabolites (1)
- miRNAs (1)
- microglia (1)
- monogenic disorders (1)
- nanobodies (1)
- natural cytotoxicity (1)
- neurogenesis (1)
- neurons (1)
- neutralization (1)
- oncogenes (1)
- passive immunization (1)
- peptide aptamer (PA) (1)
- posttranslational modification (1)
- pre-clinical models (1)
- preclinical (1)
- prophylactic vaccine (1)
- protein/lentiviral transduction (1)
- radioresponse (1)
- radiotherapy (1)
- rapamycin (1)
- rhabdomyosarcoma (1)
- signal transducer and activator of transcription 5 (Stat5) (1)
- spectroscopy (1)
- stem cell niche (1)
- stem cell therapy (1)
- stem/progenitor cell expansion (1)
- subventricular zone (1)
- targeted therapy (1)
- transcription factors (1)
- tumor microenviroment (1)
- tumor-specific antigen expressing dendritic cells (1)
- vector (1)
- viral vectors (1)
Institute
- Georg-Speyer-Haus (57) (remove)
Human endogenous retrovirus (HERV) genomes are chromosomally integrated in all cells of an individual. They are normally transcriptionally silenced and transmitted only vertically. Enhanced expression of HERV-K accompanied by the emergence of anti-HERV-K-directed immune responses has been observed in tumor patients and HIV-infected individuals. As HERV-K is usually not expressed and immunological tolerance development is unlikely, it is an appropriate target for the development of immunotherapies. We generated a recombinant vaccinia virus (MVA-HKenv) expressing the HERV-K envelope glycoprotein (ENV), based on the modified vaccinia virus Ankara (MVA), and established an animal model to test its vaccination efficacy. Murine renal carcinoma cells (Renca) were genetically altered to express E. coli beta-galactosidase (RLZ cells) or the HERV-K ENV gene (RLZ-HKenv cells). Intravenous injection of RLZ-HKenv cells into syngenic BALB/c mice led to the formation of pulmonary metastases, which were detectable by X-gal staining. A single vaccination of tumor-bearing mice with MVA-HKenv drastically reduced the number of pulmonary RLZ-HKenv tumor nodules compared to vaccination with wild-type MVA. Prophylactic vaccination of mice with MVA-HKenv precluded the formation of RLZ-HKenv tumor nodules, whereas wild-type MVA-vaccinated animals succumbed to metastasis. Protection from tumor formation correlated with enhanced HERV-K ENV-specific killing activity of splenocytes. These data demonstrate for the first time that HERV-K ENV is a useful target for vaccine development and might offer new treatment opportunities for diverse types of cancer.